ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,308.13
0.00%
Dow Jones
39,806.77
0.00%
US Dollar vs MXN
16.5598
0.03%
Brent Oil
82.63
-1.08%
Bitcoin
70,914.25
-0.75%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. AzurRx BioPharma Inc (AZRX)

  7. AzurRx BioPharma Inc (AZRX) Noticias

AZRX

AzurRx BioPharma (AZRX)

AzurRx BioPharma Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:AZRX
FechaHoraFuenteTítuloSímboloCompañía
27/06/202316:04Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:AZRXAzurRx BioPharma Inc
23/06/202315:06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AZRXAzurRx BioPharma Inc
20/06/202315:26Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:AZRXAzurRx BioPharma Inc
05/06/202306:01Edgar (US Regulatory)Securities Registration Statement (s-1)NASDAQ:AZRXAzurRx BioPharma Inc
15/05/202316:21Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:AZRXAzurRx BioPharma Inc
12/05/202307:33Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:AZRXAzurRx BioPharma Inc
05/04/202315:18Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:AZRXAzurRx BioPharma Inc
04/04/202316:29Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:AZRXAzurRx BioPharma Inc
28/03/202305:05Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:AZRXAzurRx BioPharma Inc
23/03/202316:00Edgar (US Regulatory)Small Company Offering and Sale of Securities Without Registration (d)NASDAQ:AZRXAzurRx BioPharma Inc
20/03/202315:11Edgar (US Regulatory)Annual Report (10-k)NASDAQ:AZRXAzurRx BioPharma Inc
09/01/202308:23Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:AZRXAzurRx BioPharma Inc
07/12/202215:17Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:AZRXAzurRx BioPharma Inc
28/11/202217:42Edgar (US Regulatory)Securities Registration (section 12(g)) (8-a12g)NASDAQ:AZRXAzurRx BioPharma Inc
11/10/202207:13Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(4) (424b4)NASDAQ:AZRXAzurRx BioPharma Inc
22/09/202207:56Edgar (US Regulatory)Securities Registration Statement (s-1/a)NASDAQ:AZRXAzurRx BioPharma Inc
25/07/202216:28Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:AZRXAzurRx BioPharma Inc
15/07/202215:42Edgar (US Regulatory)Proxy Soliciting Materials (revised) (prer14a)NASDAQ:AZRXAzurRx BioPharma Inc
17/05/202215:35Edgar (US Regulatory)Notification That Quarterly Report Will Be Submitted Late (nt 10-q)NASDAQ:AZRXAzurRx BioPharma Inc
02/03/202217:02Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:AZRXAzurRx BioPharma Inc
01/03/202217:16Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:AZRXAzurRx BioPharma Inc
21/09/202111:47GlobeNewswire Inc.AzurRx BioPharma to Change Corporate Name to First Wave BioPharma TodayNASDAQ:AZRXAzurRx BioPharma Inc
14/09/202106:30GlobeNewswire Inc.AzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave Bio and Creation of First Wave BioPharmaNASDAQ:AZRXAzurRx BioPharma Inc
13/09/202105:00GlobeNewswire Inc.AzurRx BioPharma Announces Acquisition of First Wave Bio and its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease IndicationsNASDAQ:AZRXAzurRx BioPharma Inc
10/09/202111:45GlobeNewswire Inc.AzurRx BioPharma Announces Reverse Stock SplitNASDAQ:AZRXAzurRx BioPharma Inc
10/09/202107:30GlobeNewswire Inc.AzurRx BioPharma Activates New Clinical Trial Sites in India for Phase 2 RESERVOIR Trial Evaluating Niclosamide for the Treatment of COVID-19 Gastrointestinal InfectionsNASDAQ:AZRXAzurRx BioPharma Inc
09/09/202107:30GlobeNewswire Inc.AzurRx BioPharma Announces Positive Results from Independent Data Monitoring Committee Review of Safety Data from Part 1 of RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal InfectionsNASDAQ:AZRXAzurRx BioPharma Inc
07/09/202115:30GlobeNewswire Inc.AzurRx BioPharma to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment ConferenceNASDAQ:AZRXAzurRx BioPharma Inc
18/08/202106:05GlobeNewswire Inc.AzurRx BioPharma Announces Positive Topline Data For Phase 2 MS1819 Combination Therapy Trial in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency (EPI)NASDAQ:AZRXAzurRx BioPharma Inc
17/08/202106:00GlobeNewswire Inc.AzurRx BioPharma Announces WHO Publication of “Adrulipase Alfa” as International Nonproprietary Name for MS1819NASDAQ:AZRXAzurRx BioPharma Inc
 Showing the most relevant articles for your search:NASDAQ:AZRX

Su Consulta Reciente

NASDAQ
AAPL
Apple
AMEX
SPY
SPDR S&P 500
FX
EURMXN
Euro vs MXN
PM
XAUUSD
Gold vs US Dollar
NASDAQ
GOOGL
Alphabet
CCOM
US500
US 500
NYSE
BAC
Bank of America
NYSE
CVX
Chevron
NYSE
MCD
McDonalds
AMEX
XLV
Health Care Select Sector
USOTC
RHHBY
Roche (QX)
USOTC
BNPQY
BNP Paribas (QX)
USOTC
DTEGY
Deutsche Telekom (QX)
AMEX
XLF
Financial Select Sector
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NYSE
JPM
JP Morgan Chase
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados